Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | J. Powderly M.R. Patel J.J. Lee J. Brody F. Meric-Bernstam E. Hamilton S. Ponce Aix J. Garcia-Corbacho Y-J. Bang M-J. Ahn S.Y. Rha K-P. Kim M. Gil Martin H. Wang A. Lazorchak T. Wyant A. Ma S. Agarwal D. Tuck A. Daud | ||||||||||||
Title | CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study | ||||||||||||
|
|||||||||||||
URL | https://academic.oup.com/annonc/article/28/suppl_5/mdx376.007/4109221 | ||||||||||||
Abstract Text | Ann Oncol. 2017 Sep 18; 28 (Suppl_5): Abstract 1141PD |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CA-170 | AUPM 170 | Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 | CA-170 is a small molecule inhibitor of PD-L1 (CD274) and VISTA (VSIR), which may stimulate T-cell mediated immune response against tumor cells (Ann Oncol. 2017 Sep 18; 28 (Suppl_5): Abstract 1141PD, PMID: 32554470). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|